Köbel M - Search Results

1

Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis.

Luchini C, Veronese N, Solmi M, Cho H, Kim JH, Chou A, Gill AJ, Faraj SF, Chaux A, Netto GJ, Nakayama K, Kyo S, Lee SY, Kim DW, Yousef GM, Scorilas A, Nelson GS, Köbel M, Kalloger SE, Schaeffer DF, Yan HB, Liu F, Yokoyama Y, Zhang X, Pang D, Lichner Z, Sergi G, Manzato E, Capelli P, Wood LD, Scarpa A, Correll CU. Luchini C, et al. Among authors: kobel m. Oncotarget. 2015 Nov 17;6(36):39088-97. doi: 10.18632/oncotarget.5142. Oncotarget. 2015. PMID: 26384299 Free PMC article. Review.

2

Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma.

Prentice LM, Klausen C, Kalloger S, Köbel M, McKinney S, Santos JL, Kenney C, Mehl E, Gilks CB, Leung P, Swenerton K, Huntsman DG, Aparicio SA. Prentice LM, et al. Among authors: kobel m. BMC Med. 2007 Nov 15;5:33. doi: 10.1186/1741-7015-5-33. BMC Med. 2007. PMID: 18005407 Free PMC article.

3

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, Santos J, Le N, Moravan V, Swenerton K; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency. Gilks CB, et al. Among authors: kobel m. Hum Pathol. 2008 Aug;39(8):1239-51. doi: 10.1016/j.humpath.2008.01.003. Epub 2008 Jul 7. Hum Pathol. 2008. PMID: 18602670

4

Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas.

Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG, Köbel M. Weichert W, et al. Among authors: kobel m. Neoplasia. 2008 Sep;10(9):1021-7. doi: 10.1593/neo.08474. Neoplasia. 2008. PMID: 18714364 Free PMC article.

5

A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary.

Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB. Köbel M, et al. Am J Surg Pathol. 2009 Jan;33(1):14-21. doi: 10.1097/PAS.0b013e3181788546. Am J Surg Pathol. 2009. PMID: 18830127

6

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.

Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. Köbel M, et al. PLoS Med. 2008 Dec 2;5(12):e232. doi: 10.1371/journal.pmed.0050232. PLoS Med. 2008. PMID: 19053170 Free PMC article.

7

IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype.

Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IeM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB. Köbel M, et al. Mod Pathol. 2009 Mar;22(3):469-75. doi: 10.1038/modpathol.2008.206. Epub 2009 Jan 9. Mod Pathol. 2009. PMID: 19136932 Free article.

8

Mutation of FOXL2 in granulosa-cell tumors of the ovary.

Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG. Shah SP, et al. Among authors: kobel m. N Engl J Med. 2009 Jun 25;360(26):2719-29. doi: 10.1056/NEJMoa0902542. Epub 2009 Jun 10. N Engl J Med. 2009. PMID: 19516027 Free article.

9

Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications.

Köbel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD. Köbel M, et al. Gynecol Oncol. 2010 Jan;116(1):50-6. doi: 10.1016/j.ygyno.2009.09.029. Epub 2009 Oct 12. Gynecol Oncol. 2010. PMID: 19822358

10

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.

McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Köbel M, Kalloger SE, Swenerton KD, Huntsman DG, Gilks CB, Miller DM. McAlpine JN, et al. Among authors: kobel m. BMC Cancer. 2009 Dec 10;9:433. doi: 10.1186/1471-2407-9-433. BMC Cancer. 2009. PMID: 20003286 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

594 results

Search Page

Filters